

7. An effervescent formulation according to any of the preceding claims wherein the desmopressin is present in a unit dose amount of from 1 μg to 1500 μg .
- 5 8. An effervescent formulation according to Claim 7 wherein the desmopressin is present in a unit dose amount of 100 μg to 400 μg .
9. An effervescent formulation according to any of the preceding claims wherein the formulation is presented in a tablet form.
- 10 10. An effervescent formulation according to Claims 1 to 8 wherein the formulation is presented in a powder form.
11. An effervescent formulation according to any one of the preceding
15 claims wherein the desmopressin is present within a microsphere.
12. An effervescent formulation according to any one of Claims 1 to 11 wherein the desmopressin is not present within a microsphere.
- 20 13. An effervescent formulation according to any of the preceding claims obtained or obtainable by the process of any one of Claims 16 to 25.
14. An effervescent formulation according to any one of the previous claims for use in medicine.
- 25 15. A pharmaceutical composition comprising an effervescent formulation according to any one of Claims 1 to 13 and a pharmaceutically acceptable carrier.

16. A process for making an effervescent formulation containing desmopressin.

17. A process according to Claim 16 wherein the effervescent
5 formulation comprises multilayer effervescent microspheres containing an acidic substance, a basic substance, and a water-soluble isolating agent which upon dissolution in water leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of desmopressin.

10 18. A process according to Claim 17 wherein the acidic and/or basic substances contains or contain desmopressin.

19. A process according to Claim 16 or Claim 17 wherein the desmopressin is not present in microspheres.

15

20. A process according to Claim 18 which employs the method of rotary granulation in a fluidized air bed.

21. A process according to Claims 17 to 20 wherein basic substance also
20 contains an edible diluant and/or flavourings and/or sweeteners.

22. A process according to Claims 17 to 21 wherein the desmopressin is present in an amount to give from 1µg to 100 µg in the final unit dosage form.

25

23. A process according to Claim 22 wherein the desmopressin is present in an amount to give from 100µg to 400µg in the final unit dosage form.

24. A process according to any one of Claims 16 to 23 further comprising preparing the microspheres into a tablet.

25. A process according to Claim 24 wherein the desmopressin is present on or between the microspheres in the tablet.

26. An effervescent formulation of desmopressin obtained or obtainable by the process of any one of Claims 16 to 25.

27. A method of treating diabetes insipidus, nocturnal enuresis, postoperative polyuria or polydipsia, nocturia associated with multiple sclerosis, mild to moderate haemophilia or von Willebrand's disease by administering an effervescent formulation of desmopressin.

28. Use of an effervescent formulation of desmopressin in the manufacture of a medicament for treating diabetes insipidus, nocturnal enuresis, postoperative polyuria or polydipsia, nocturia associated with multiple sclerosis, mild to moderate haemophilia or von Willebrand's disease.